 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Hyseq, Inc.
 |
Hyseq, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Hyseq posts widened Q2 loss, says to cut workforce Jul 26 2001 06:35 AM PDT
> More WIRE STORIES about this company
NEWS FROM THE STANDARD |
 |
DNA Detectives
May 22 2000 12:00 AM PDT
Planet Web: Battle of the Gene Genies
Nov 14 1999 12:00 AM PST
PROFILE |
 |
No hijinks for Hyseq. The company develops gene-based drugs, databases, and tests using its proprietary DNA array technology. Its databases focus on rarely expressed genes and polymorphisms (variations in DNA) relating primarily to cardiovascular disease. Its drug pipeline includes candidates targeting heart disease, cancer, and inflammatory and infectious diseases. With partner Chiron, Hyseq is developing cancer therapies and vaccines. Its partnership with BASF Plant Sciences, which accounts for 75% of its collaborative revenues, focuses on gene-based agriculture products; with Applied Biosystems it is developing the HyChip universal sequencing chip. Chairman George Rathmann owns about 20% of the firm.
COMPETITION |
 |
Affymetrix, Inc. (AFFX)
Applied Biosystems Group (ABI)
Incyte Genomics, Inc. (INCY)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 15.60
1-Yr. Sales Growth: 143.8%
Employees: 257
Revenue per employee: $60,700.39
KEY PEOPLE |
 |
Ted W. Love
CEO
Peter S. Garcia
CFO
CONTACT INFO |
 |
670 Almanor Ave.
Sunnyvale, CA 94086
US
Phone: 408-524-8100
Fax: 408-524-8141
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |